Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16994747 | 0.83 | KMT2A (0.73) | GAAKMT2ANPSR1LMNA | |
| SCHEMBL27645392 | 0.83 | HDAC2 (0.49) | GAAKMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL7604703 | 0.82 | HDAC1 (0.63) | HDAC1HDAC2HDAC3 | |
| SCHEMBL2590028 | 0.80 | HDAC2 (0.51) | GAAKMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL13738325 | 0.79 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL29848538 | 0.78 | HDAC1 (0.59) | KMT2AHDAC1HDAC2HDAC3LMNA | |
| SCHEMBL25668704 | 0.78 | KMT2A (0.70) | GAAKMT2ANPSR1LMNA | |
| SCHEMBL13833695 | 0.78 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL20460484 | 0.78 | KMT2A (0.74) | GAAKMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL13833436 | 0.77 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | GAA 2237/4885KMT2A 4772/4885HDAC1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.